Press Releases

05/12 "A Change Is A Change" – The Supreme Court Rejects A Narrow Interpretation Of "Material Change" AQ
25/25/25 Theratechnologies Announces Completion of Acquisition by Future Pak AQ
17/25/17 Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak AQ
12/25/12 Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak AQ
05/25/05 Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy AQ
02/25/02 Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak AQ
18/25/18 Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak AQ
09/25/09 Theratechnologies : Q2 Interim Consolidated May 31, 2025vFINAL PU
09/25/09 Theratechnologies : MDA Q2 2025 VFINAL PU
09/25/09 Theratechnologies: Fiscal Q2 Earnings Snapshot AQ
09/25/09 Theratechnologies Reports Financial Results for the Second Quarter 2025 AQ
04/25/04 Theratechnologies to Announce Second Quarter 2025 Financial Results AQ
03/25/03 Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak AQ
29/25/29 Theratechnologies Reports on its Annual Meeting of Shareholders AQ
03/25/03 Theratechnologies : Thera Circular 2025 vFINAL PU
02/25/02 Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV AQ
16/25/16 Theratechnologies Provides Update on Sale Process AQ
14/25/14 Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value AQ
12/25/12 Soleus Capital Issues Letter to The Board of Theratechnologies BU
12/25/12 Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company AQ
10/25/10 Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements AQ
09/25/09 Theratechnologies Receives FDA Approval of Prior Approval Supplement for EGRIFTA SV sBLA AQ
09/25/09 Theratechnologies : Quarterly Management's Discussion & Analysis Q1 PU
09/25/09 Theratechnologies : Q1 Interim Consolidated February 28, 2025 VFINAL PU
09/25/09 Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements AQ
No results for this search